

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12Q 1/68		A1	(11) International Publication Number: WO 98/50583 (43) International Publication Date: 12 November 1998 (12.11.98)
(21) International Application Number: PCT/US98/08853 (22) International Filing Date: 1 May 1998 (01.05.98)		(81) Designated States: AU, CA, JP, KR, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 60/045,430 2 May 1997 (02.05.97) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant: GEN-PROBE INCORPORATED [US/US]; 10210 Genetic Center Drive, San Diego, CA 92121-4362 (US).			
(72) Inventors: WEISBURG, William, G.; 11738 Via Medanos, San Diego, CA 92128 (US). SHAW, Jay, H.; 17844 Creciente Way, San Diego, CA 92127 (US). BECKER, Michael, M.; 12819 Meadowdale Lane, San Diego, CA 92131 (US). MAJLESSI, Mehrdad; 15895 Sunnyfield Place, San Diego, CA 92127 (US).			
(74) Agents: GRITZMACHER, Christine, A. et al.; Gen-Probe Incorporated, Patent Dept., 10210 Genetic Center Drive, San Diego, CA 92121-4362 (US).			
(54) Title: TWO-STEP HYBRIDIZATION AND CAPTURE OF A POLYNUCLEOTIDE			
<p>3' AAAAAAAAAAAATTGTCAGTAACCTTGATTCAAG 5' 10 TTTTTTTTTTTTT 3' (a)</p>			
<p>5' ... NNNNNNN TTTTTTTTTTTTT 3' CAGTCATTGGAACCTAAGTAGTAGTTCCNNNNNN... 3' (b)</p>			
<p>3' AAAAAAAAAAAATTGTCAGTAACCTTGATTCAAG 5' TTTTTTTTTTTTT 3' (c)</p>			
(57) Abstract			
<p>A method for capturing a target polynucleotide in a sample onto a solid support with an attached immobilized probe by using a capture probe and two different hybridization conditions, which preferably differ in temperature only, is disclosed. The two hybridization conditions control the order of hybridization, where the first hybridization condition allows the capture probe and the target polynucleotide to hybridize, and the second hybridization condition allows the capture probe and the immobilized probe to hybridize, to produce a complex of immobilized probe, capture probe and target polynucleotide. A method for determining the presence of a target polynucleotide in a sample by capturing a target polynucleotide, amplifying the captured target polynucleotide and detecting amplified sequences is also disclosed.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Malta	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KI	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

TWO-STEP HYBRIDIZATION AND CAPTURE OF A POLYNUCLEOTIDE

Field of the Invention

5 The present invention relates to methods for capturing a polynucleotide which may be present in a sample onto a solid support. The invention is particularly useful for separating a target polynucleotide from other material in a sample, and is preferably employed as part of a diagnostic procedure to detect the presence of the target polynucleotide in a sample.

Background of the Invention

10 A target polynucleotide is a polynucleotide present in a sample that can be purified from one or more sample components and/or whose presence can be detected using different techniques. Such techniques are typically carried out as part of a diagnostic procedure to detect the presence of a target polynucleotide which is indicative of the presence of an infectious agent or pathogenic condition.

15 The presence of a target polynucleotide base sequence region, present in a target polynucleotide, can be detected by various methods such as those using nucleic acid probes that hybridize to a target sequence. Probes can be designed to detect different target sequences such as those characteristic of microorganisms, viruses, human genes, plant or animal genes, and/or pathogenic conditions.

20 A technique for purifying a target polynucleotide, which is often used in diagnostic procedures, involves capturing a target polynucleotide onto a solid support. The solid support retains the target polynucleotide during one or more washing steps of the target polynucleotide purification procedure.

25 Ranki *et al.*, U.S. Pat. No. 4,486,539 describe a hybridization sandwich technique for capturing and for detecting the presence of a target polynucleotide. The technique involves the capture of the target polynucleotide by a probe bound to a solid support and hybridization of a detection probe to the captured target polynucleotide. Detection probes not hybridized to the target polynucleotide are readily washed away from the solid support. Thus, remaining label is associated with the target polynucleotide initially present in the sample.

30 Stabinsky, U.S. Pat. No. 4,751,177 describes a method that uses a mediator polynucleotide that hybridizes to both a target polynucleotide and to a polynucleotide fixed on a solid support. The mediator polynucleotide joins the target polynucleotide to the solid support to produce a bound target. A labeled probe can be hybridized to the bound target and unbound labeled probe can be washed away from the solid support.

Englehardt *et al.*, U.S. Pat. Nos. 4,894,324 and 5,288,609, describe a method for detecting a target polynucleotide. The method utilizes two single-stranded polynucleotide segments complementary to the same or opposite strands of the target and results in the formation of a double hybrid with the target polynucleotide. In one embodiment, the double hybrid can be captured onto a support.

5 Cape *et al.*, EP Pat. Pub. No. 0 370 694, describe methods and kits for detecting nucleic acids using a solid phase capture means. The methods use oligonucleotide primers labeled with specific binding partners to immobilize primers and primer extension products. The label specifically complexes with its receptor which is bound to a solid support.

Summary of the Invention

10 According to one aspect of the invention, there is disclosed a method of capturing a target polynucleotide present in a sample, including the steps of: incubating a mixture that includes a target polynucleotide, a capture probe, and an immobilized probe in a first hybridization condition that favors formation of a capture probe:target hybridization complex made of the capture probe and the target polynucleotide, and disfavors formation of an immobilized probe:capture probe hybridization complex made of the immobilized probe and the capture probe; and then incubating the mixture in a second hybridization condition that favors formation of the immobilized probe:capture probe hybridization complex, thereby capturing the target polynucleotide in an immobilized probe:capture probe:target hybridization complex made of the immobilized probe, the capture probe and the target polynucleotide. In one embodiment, the first incubating step uses a temperature below a T_m of the polynucleotide. In one embodiment, the first incubating step uses a temperature below a T_m of the capture probe:target hybridization complex and above a T_m of the immobilization probe:capture probe hybridization complex, and the second incubating step uses a temperature below a T_m of the immobilization probe:capture probe hybridization complex. Preferably, the second incubating step is achieved by lowering the temperature of the first hybridization condition by at least about 10°C, or by at least about 20°C. In one embodiment, the first incubating step uses a temperature of about 60°C and the second incubating step uses a temperature of about 40°C or lower. The method may also include the step of purifying the immobilized probe:capture probe:target hybridization complex. Other embodiments of the method include the step of detecting the target polynucleotide in the immobilized probe:capture probe:target hybridization complex by hybridizing a labeled probe to the target polynucleotide and detecting the labeled probe. The method may also include the step of amplifying the target polynucleotide to produce an amplified nucleic acid, preferably by transcription-associated amplification. When the amplifying step is included, the method may also include the step of detecting the amplified nucleic acid which preferably, includes the steps of hybridizing a

labeled probe to the amplified nucleic acid which is complementary to the target polynucleotide and detecting the labeled probe. The method may also include in the detecting step a step of removing unhybridized labeled probe. In preferred embodiments, both incubating steps include using the immobilized probe which includes a capture probe-binding region of at least five nucleotide base

5 recognition groups in length, and the capture probe which includes an immobilized probe-binding region of at least five nucleotide base recognition groups in length, provided that the capture probe-binding region is complementary to the immobilized probe-binding region. Preferably, the capture probe-binding region comprises: (a) a first backbone containing at least one sugar-phosphodiester linkage, or at least one peptide nucleic acid group, at least one phosphorothioate linkage, or a combination thereof, and (b) at least ten nucleotide base recognition groups joined to the first

10 backbone, wherein each nucleotide recognition group is capable of hydrogen bonding with adenine, guanine, cytosine, thymine, uracil or inosine; and the immobilized probe-binding region comprises: (a) a second backbone containing at least one sugar-phosphodiester linkage, or at least one peptide nucleic acid group, at least one phosphorothioate linkage, or a combination thereof, and (b) at least

15 ten nucleotide base recognition groups joined to the second backbone, which are capable of hydrogen bonding to the nucleotide base recognition groups joined to the first backbone. In one embodiment of the method, the capture probe-binding region consists of a homopolymer comprising at least 10 nucleotides, and the immobilized probe-binding region consists of a homopolymer comprising at least 25 nucleotides, of which at least 10 nucleotides are complementary to the 10

20 nucleotides of the capture probe-binding region. Preferably, the capture probe-binding region includes about fourteen contiguous A or T bases, and the immobilized probe-binding region includes a sequence of about 30 bases complementary thereto. In preferred embodiments, the incubating steps use a mixture of the immobilized probe and the capture probe, in which each probe includes deoxynucleotides, ribonucleotides, 2'-methoxy substituted nucleotides, 2'-halo substituted nucleotide

25 components, or combinations thereof.

Another aspect of the invention is a method for determining the presence of a target polynucleotide in a sample. This method includes the steps of: providing a capture probe capable of hybridizing to a target polynucleotide present in a sample; mixing the capture probe with a sample suspected of containing the target polynucleotide at a first incubation temperature that favors

30 hybridization of the capture probe and the target polynucleotide, thereby producing a capture probe:target polynucleotide complex; providing an immobilized probe capable of hybridizing to the capture probe; incubating the capture probe:target polynucleotide complex and the immobilization probe at a second incubation temperature that favors hybridization of the immobilized probe and the

capture probe, thereby producing a captured target polynucleotide comprising an immobilized probe:capture probe:target polynucleotide complex; purifying the captured target polynucleotide, thereby producing a purified target polynucleotide; amplifying the purified target polynucleotide, thereby producing an amplified nucleic acid; and detecting the amplified nucleic acid to determine 5 the presence of the target polynucleotide in the sample. In one embodiment of this method, the detecting step includes hybridizing a labeled probe to the amplified nucleic acid which is complementary to the target polynucleotide or a portion thereof and detecting the labeled probe.

Brief Description of the Drawings

FIGS. 1A and B schematically illustrate the use of two different hybridization conditions to 10 capture a target polynucleotide, labeled "(c)", using an immobilized probe, labeled "(a)", attached to a solid support 10, and a capture probe, labeled "(b)". In FIG. 1A, the first hybridization condition permits hybridization of capture probe (b) and target polynucleotide (c) to form a capture probe:target polynucleotide complex 15, but does not permit hybridization of capture probe (b) and immobilized probe (a). In FIG. 1B, the second hybridization condition permits hybridization of 15 capture probe (b) and immobilized probe (a) to form an immobilized probe:capture probe:target polynucleotide complex 20.

FIG. 2 illustrates steps A through F of a method that includes amplification of a captured target polynucleotide sequence (step (A)) using transcription-associated amplification (steps (B) to (F)). In FIG. 2, step (A), an immobilized probe (a) attached to a solid support 10, capture probe (b), 20 and target polynucleotide sequence (c) are labeled as in FIG. 1. A promoter sequence recognized by an RNA polymerase is labeled "P"; "(-)" indicates the 5' end of a nucleic acid and "(+)" indicates the 3' end of a complementary nucleic acid; and a dashed line "(--)" indicates nucleic acid polymerization.

FIGS. 3A, 3B and 3C illustrate the use of two different hybridization conditions to detect the 25 presence of a target polynucleotide (c), using an immobilized probe (a), attached to solid support 10, a capture probe (b), labeled as in FIG. 1, and labeled probes shown as "(d)". In FIG. 3A, the first hybridization condition allows formation of a capture probe:target polynucleotide:labeled probe complex 30. In FIG. 3B, a second hybridization condition allows formation of an immobilized probe:capture probe:target polynucleotide:labeled probe complex 40, leaving unbound labeled 30 probes 50. In FIG. 3C, the unbound labeled probes have been washed away, leaving the purified immobilized probe:capture probe:target polynucleotide:labeled probe complex 40.

FIG. 4 illustrates an example of a solid support 10 with attached immobilized probes consisting of T₁₄ sequences; the upper probe (adjacent to "(a)" at the right side) is in immobilized

probe:capture probe complex in which the T₁₄ immobilized probe is hybridized (shown as ":" between bases) to a capture probe (3' A₁₄TTTGTCACTAACCTTGATTCAAG 5' (SEQ ID NO:1)) containing a complementary A₁₄ sequence; the middle probe (adjacent to "(b)" at the right side) is in an immobilized probe:capture probe:target polynucleotide complex which contains the immobilized probe hybridized to the capture probe which is hybridized to a target sequence (5' CAGTCATTGGAACTAAGTAGTTC 3' (SEQ ID NO:2)) within a larger sequence (indicated by terminal "NNNNNN" sequences); and the lower probe (adjacent to "(c)" at the right side) is an unhybridized immobilized T₁₄ probe.

Detailed Description of the Invention

10 The present invention features methods for capturing a target polynucleotide onto a solid support using a capture probe and two different hybridization conditions. Different hybridization conditions are used to control the order of hybridization in a sample containing a target polynucleotide, mixed with a capture probe and an immobilized probe. By a "hybridization condition" is meant the cumulative environment used for a reaction in which one single-stranded nucleic acid 15 hydrogen bonds to a second single-stranded nucleic acid to produce a hybridization complex (which is sometimes referred to herein as a "complex"). The cumulative environment includes, for example, the concentrations and components (e.g., salts, chelating agents and noncompetitive inhibitor nucleic acids) of an aqueous or organic solution containing the single-stranded nucleic acids, and the temperature of the reaction mixture. Other factors that may contribute to the cumulative 20 environment include, for example, the amount of time in which hydrogen bonding is allowed to occur, the physical geometry of the chamber holding the reactants, and the use of mixing or agitation during hybridization. All of these environmental conditions are well known in the art (e.g., See Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual*, 2nd ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989)). In the present invention, the first hybridization 25 condition facilitates hybridization of the capture probe to the target polynucleotide while essentially precluding hybridization of the capture probe and the immobilized probe, and a second hybridization condition then facilitates hybridization of the capture probe and the immobilized probe.

An immobilized probe provides means for joining a capture probe to an immobilized support. The immobilized probe is a base sequence recognition molecule joined to a solid support which 30 facilitates separation of bound target polynucleotide from unbound material. Any known solid support may be used, such as matrices and particles free in solution. For example, solid supports may be nitrocellulose, nylon, glass, polyacrylate, mixed polymers, polystyrene, silane polypropylene and, preferably, magnetically attractive particles. Particularly preferred supports are magnetic

spheres that are monodisperse (*i.e.*, uniform in size \pm about 5%), thereby providing consistent results, which is particularly advantageous for use in an automated assay.

The immobilized probe is joined directly, or indirectly, to a solid support by a linkage or interaction which is stable during the first and second hybridization conditions used in the present invention. Direct joining occurs when the immobilized probe molecule is joined to the solid support in the absence of an intermediate group. For example, direct joining may be via a covalent linkage, chelation, or ionic interaction. Indirect joining occurs when the immobilized probe is joined to the solid support by one or more linkers. A "linker" is a means for binding at least two different molecules into a stable complex and contains one or more components of a binding partner set.

Members of a binding partner set are able to recognize and bind to each other. Binding partner sets may be, for example, receptor and ligand, enzyme and substrate, enzyme and cofactor, enzyme and coenzyme, antibody and antigen, sugar and lectin, biotin and streptavidin, ligand and chelating agent, nickel and histidine, substantially complementary nucleotide base recognition molecules, and complementary homopolymeric nucleic acids or homopolymeric portions of polymeric nucleic acids. Components of a binding partner set are the regions of the members that participate in binding.

The methods of the present invention have many different embodiments. In one, a linker is directly joined to the solid support, and is joined to the immobilized probe through components of a binding pair set. In another embodiment, more than one linker is present, where a first linker is directly joined to the solid support and at least one second linker is joined to the immobilized probe through components of a binding pair set. Additional linkers may be used to join the first and second linkers.

A "base sequence recognition molecule" is a polymer containing nucleotide base recognition groups linked together by a backbone. The nucleotide base recognition groups provide sequence information for hybridizing with a complementary molecule. An individual nucleotide base recognition group can hydrogen bond to adenine (A), guanine (G), cytosine (C), thymine (T), uracil (U) or derivatives thereof. The backbone of a base sequence recognition molecule provides the nucleotide base recognition groups with the proper orientation and spacing for hydrogen bonding during hybridization, particularly to bases of a nucleic acid. Base sequence recognition molecules may be, *e.g.*, RNA, DNA, peptide nucleic acid, or derivatives thereof.

A capture probe provides means for stably joining a target polynucleotide and an immobilized probe. The capture probe includes one or more base sequence recognition portions: a target polynucleotide-binding region and an immobilized probe-binding region. These two binding

regions may be present on one or more base sequence recognition molecules, but preferably are included in a single base sequence recognition molecule containing the two binding regions. In another embodiment, the capture probe includes a target polynucleotide-binding region and an immobilized probe-binding region which are present on two different base sequence recognition molecules joined together by one or more linkers. For example, an immobilized probe-binding region may be present on a first base sequence recognition molecule, the target polynucleotide-binding region may be present on a second base sequence recognition molecule, and the two different molecules are joined by a linker that is a base sequence recognition molecule that hybridizes to the first and second base sequence recognition molecules.

10 The present invention includes a method of capturing a target polynucleotide present in a sample. First, a mixture including the sample, a capture probe, and an immobilized probe is produced and incubated in a first hybridization condition to form a capture probe:target complex made up of the capture probe hybridized to the target polynucleotide. The first hybridization condition uses a temperature below the T_m of a capture probe:target complex and above the T_m of 15 an immobilized probe:capture probe hybrid. Preferably, in the first hybridization condition, less than at least 50% of the capture probe is in an immobilized probe:capture probe complex. More preferably, in the first hybridization condition, less than 25%, even more preferably, less than 10%, and, most preferably, less than 1% of the capture probe is in an immobilized probe:capture probe complex.

20 Then, a second hybridization condition is used to form an immobilized probe:capture probe:target polynucleotide complex made up of the immobilized probe hybridized to the capture probe, which is hybridized to the target polynucleotide. The temperature of the second hybridization condition is below the T_m of the immobilized probe:capture probe hybridization complex, and thus is compatible with the formation of a immobilized probe:capture probe complex. Preferably, the 25 immobilized probe is in excess relative to the capture probe.

“ T_m ” refers to the melting temperature at which 50% of hybridization complexes formed between two base sequence recognition molecules are denatured. At a temperature below the T_m , hybridization complex formation is favored, whereas at a temperature above the T_m , complex formation is not favored.

30 Reference to T_m of a hybridization complex containing a capture probe or immobilized probe includes complexes formed via hybridization with one or more linkers which may be present. If linkers are present, then the T_m of a hybridization complex reflects the overall stability of the complex, as can be readily calculated by those skilled in the art. For example, in a capture probe

made up of three oligonucleotides there is a first T_m of the first oligonucleotide hybridized to the second oligonucleotide, and a second T_m of the second oligonucleotide hybridized to a third oligonucleotide. The lower of these first and second T_m 's determines the stability of the capture probe and whether the three oligonucleotides making up the capture probe remain hybridized under a particular hybridization condition.

5 The capture probe:target polynucleotide hybridization complex, like other complexes described herein, may contain additional groups besides the indicated components. Such additional groups include, for example, a labeled probe hybridized to the target polynucleotide or an oligonucleotide hybridized to the target which is useful for amplification of the target polynucleotide.

10 Additional groups not affecting the functioning of the present invention may also be present.

A labeled probe is a base sequence recognition molecule containing a detectable group. Detectable groups may be, for example, a fluorescent moiety, a chemiluminescent moiety, a radioisotope, biotin, avidin, an enzyme or enzyme substrate, or a reactive group.

15 The methods of the present invention may further include a purifying step. By "purifying" is meant that one or more components making up the sample prior to purification are removed from one or more other components of the sample. Sample components include nucleic acids, and may also include materials such as proteins, carbohydrates, lipids and labeled probes. Preferably, the purifying step removes at least about 70%, more preferably at least about 90% and, even more preferably, at least about 95% of the non-target nucleic acid present in the sample.

20 The methods of the present invention may also include amplifying a purified target polynucleotide following capture (herein referred to as a "captured target") to produce an amplified nucleic acid. Amplifying a target nucleic acid uses a nucleic acid polymerase to produce multiple copies of the entire target polynucleotide or fragments thereof, or of a nucleic acid complementary to the entire target polynucleotide or fragments thereof. Suitable amplification techniques that are well known in the art include, for example, transcription-associated amplification, Polymerase Chain Reaction (PCR), replicase mediated amplification, and Ligase Chain Reaction (LCR).

25 Amplification of "fragments thereof" refers to production of an amplified nucleic acid containing less than the complete target polynucleotide or the complement thereof. Such fragments may be produced by amplifying a portion of the target polynucleotide, for example, by using an amplification oligonucleotide which hybridizes to, and initiates polymerization from, an internal position of the target polynucleotide. Preferably, the amplified fragment contains a detectable target sequence. The presence of amplified nucleic acid may be detected using different well known techniques, such as, for example, hybridizing a labeled probe to the amplified nucleic acid. Other

techniques well known in the art for detecting nucleic acid include, for example, gel filtration, gel electrophoresis, and High Performance Liquid Chromatography (HPLC).

A labeled probe may be used to detect the presence of a purified captured target. Preferably, a purifying step is used to remove unbound labeled probes from bound labeled probes which are hybridized to captured target polynucleotides. The purifying step may be used simultaneously with purifying the captured target polynucleotide. Alternatively, labeled probes may be added to a purified captured target polynucleotide and unbound labeled probes may be removed in a subsequent purifying step.

By "remove" in reference to a sample component or hybridization reaction component, (e.g., unbound labeled probe), is meant that at least 70% of the undesirable component is separated from a retained component. More preferably at least 90% and, even more preferably, at least 95% of the undesirable component is removed. Components may be removed, using standard procedures such as, for example, by using a washing procedure.

The presence of the captured target polynucleotide may be detected using a homogeneous detectable label which may be positioned on the capture probe or on a separate detection probe. A "homogeneous detectable label" refers to a label whose presence can be detected in a homogeneous fashion based upon whether the label is on a molecule hybridized to the target polynucleotide. Thus, the homogeneous detectable label can be detected without physically removing hybridized from unhybridized forms of the label. Homogeneous detectable labels have been previously described, including examples in Arnold *et al.*, U.S. Pat. No. 5,283,174; Woodhead *et al.*, U.S. Pat. No. 5,656,207; and Nelson *et al.*, U.S. Pat. No. 5,658,737.

The immobilized probe may contain one or more repetitious base sequences that are complementary to one or more repetitious base sequences of the capture probe. These complementary repetitious sequences preferably are sequences of at least five bases in length and serve as binding regions (*i.e.*, a capture probe-binding region of the immobilized probe, and an immobilized probe-binding region of the capture probe). The complementary repetitious sequences of the immobilized and capture probes facilitate hybridization between the two probes.

A "repetitious" sequence refers to a sequence of regularly repeating base sequences, such as those formed, for example, by nucleic acid homopolymers of poly-adenine (A_n), poly-thymine (T_n), poly-cytosine (C_n), and poly-guanine (G_n). Repetitious sequences also include those of nucleic acid mixed polymers, such as AT repeats ($[AT]_n$).

Preferably, the repetitious base sequence of the capture probe is longer than a complementary repetitious base sequence of the immobilized probe. The lengths of the



complementary repetitious sequences of the two probes determine the T_m of the immobilized probe:capture probe complex. The longer repetitious base sequence of the capture probe facilitates binding to the repetitious base sequence of the immobilized probe because the additional length provides distance between secondary structure of a target polynucleotide that otherwise interferes with hybridization to the immobilized probe. Preferably, the repetitious base sequence of the immobilized probe is at least about 10 bases, even more preferably about 14 bases in length; and the repetitious base sequence of the complementary capture probe is at least about 10 bases, more preferably is at least about 14 bases, even more preferably is at least about 25 bases in length, and most preferably is about 30 bases in length.

10 A method of the present invention is used to determine whether a target polynucleotide is present in a sample. The method includes a target capture step that includes two hybridizations, a purifying step, an optional amplifying step and a detecting step. In the presence of a target polynucleotide, in the first hybridization a capture probe:target polynucleotide complex is produced, and in the second hybridization an immobilized probe hybridizes with the capture probe. Thus, in 15 the presence of a target polynucleotide, the target capture step results in the formation of an immobilized probe:capture probe:target complex comprising an immobilized probe, a capture probe, and a target polynucleotide. If no target polynucleotide is present, then this immobilized probe:capture probe:target complex is not formed and only the immobilized probe:capture probe complex of the second hybridization is formed. The complex formed during the target capture step 20 is purified to produce a purified target polynucleotide for samples containing target polynucleotide.

The purified target polynucleotide may be amplified and then detected, or the purified target polynucleotide may be detected without an amplification step. Preferably, the presence of the purified captured target polynucleotide or amplified nucleic acid is detected using a labeled probe. More preferably, the labeled probe hybridizes to the target polynucleotide to form a labeled 25 probe:target polynucleotide complex having a T_m above the temperature of the first hybridization condition. Detection of the labeled probe in the complex indicates the presence of the target polynucleotide in the sample.

When an optional amplification step is included in the method, the purified target polynucleotide is amplified to produce an amplified nucleic acid which is then detected using a 30 labeled probe as described above or by any of a variety of known techniques for detecting nucleic acid (e.g., visualization using a fluorescent intercalating agent). Detection of the amplified nucleic acid indicates that the target polynucleotide was initially present in the sample.

During the hybridization of a capture probe to a target polynucleotide, it is useful to have the

capture probe in solution rather than bound to a solid support to maximize the concentration of the free capture probe and to utilize favorable liquid phase hybridization kinetics known to those skilled in the art. That is, solution phase hybridization generally occurs 100-fold faster than a solid phase hybridization that uses the same complementary binding sequences. It is also desirable to add the 5 immobilized probe prior to hybridization of the capture probe to the target polynucleotide to minimize the number of reagent additions and separations, and the complexity of the chemistry. These aspects of the invention are particularly important for an automated assay.

In the methods of the present invention for capturing a target polynucleotide onto a solid support using a capture probe and two different hybridization conditions, the solid support with an 10 immobilized probe, capture probe, and target nucleic acid may be present during both hybridization conditions. The captured target nucleic acid may be purified from other material which is present by washing away the other material using conditions in which the captured target is retained. Then, the purified target polynucleotide may be eluted from the solid support using appropriate conditions, such as by incubating at a temperature above the T_m of the capture probe:immobilized probe 15 complex.

These methods are particularly useful as part of a diagnostic assay in which the target polynucleotide is amplified to produce larger amounts of amplified nucleic acids which are free in solution. The amplified nucleic acids in solution may be detected using well known techniques such as nucleic acid hybridization.

An automated diagnostic assay using the methods of the present invention may be carried 20 out, for example, by: (1) adding a sample suspected of having a target polynucleotide to a container containing a capture probe specific for the target and an immobilized probe which is joined to a solid support; (2) carrying out a two-step hybridization to capture the target polynucleotide onto the solid support by incubating in a first hybridization condition and then lowering the temperature to that of 25 the second hybridization condition; (3) removing sample components not bound to the solid support, for example, by using a washing step; (4) adding to the solid support a solution containing oligonucleotides used in nucleic acid amplification of all or a portion of the target, the appropriate solution components for carrying out amplification, and a probe which hybridizes to amplified nucleic acid and contains a homogeneous detectable label; (5) producing amplified nucleic acid; and (6) 30 detecting the amplified nucleic acid, such as by treating the sample to produce a signal from the label hybridized to the amplified nucleic acid. Detecting the signal indicates the presence of the target polynucleotide in the sample. Different variations of the above scheme may be carried out based on the disclosure provided herein.

FIGS. 1 to 3 provide schematic illustrations of the use of the present invention to capture a target polynucleotide, to optionally amplify a polynucleotide target, and to detect the presence of the polynucleotide target. Although FIGS. 1 to 3 illustrate preferred embodiments, those skilled in the art will appreciate that other variations and equivalents can be used to practice the described invention based on the descriptions provided herein. FIG. 4 shows an example of the types of complexes that can be attached to a solid support via an immobilized probe that is a homopolymer.

FIGS. 1A and 1B illustrate the capture of a target polynucleotide. At the beginning of the assay, the immobilized probe (a) is bound to a solid support particle 10, and the capture probe (b) and the target polynucleotide (c) are free in solution. Referring to FIG. 1A, in the first hybridization condition, a capture probe:target polynucleotide complex 15 is formed in solution but the capture probe (b) is substantially unbound to the immobilized probe (a). Then, the reaction is incubated in the second hybridization condition as shown in FIG. 1B. In the second hybridization condition, the capture probe (b) hybridizes to the immobilized probe (a), thereby capturing the target polynucleotide (c) in an immobilized probe:capture probe:target nucleic acid complex 20. Preferably, the second hybridization condition occurs in the same solution by lowering the temperature from that of the first hybridization condition. A specific example of the complexes that can be attached to a solid support via an immobilized probe is illustrated in FIG. 4.

FIG. 2 illustrates one embodiment that further includes amplification of a target polynucleotide sequence (c) using a transcription-associated amplification. The 5' and 3' ends of nucleic acids are indicated by (-) and (+), respectively, on the right-hand side of the figure next to lines representing nucleic acids; using this notation, strands marked “(-)” indicate antisense strands, and strands marked “(+)” indicate sense strands. The dashed line (--) terminating in an arrow (- or -) indicates nucleic acid polymerization of a complementary strand of nucleic acid.

In FIG. 2, step (A) illustrates a captured target polynucleotide (c), as described for FIG. 1B, that has been hybridized to an oligonucleotide containing a promoter sequence “P” to form a nucleic acid hybridization complex 22. Using a polymerase such as a reverse transcriptase, a complementary DNA is synthesized (shown by --). In step (B), (-) strand is hybridized to a primer 24 and reverse transcriptase is used to form a DNA duplex 23 containing a double-stranded promoter P by polymerization (shown by --). In step (B), the complex 23 is shown free in solution, although it need not be released from the solid support 10. Making the (-) strand available for hybridization with a primer 24 may be achieved using different techniques well known in the art, such as, by using a denaturing step, or RNase H activity. Preferably, RNase H activity is used when the target is an RNA polynucleotide.

FIG. 2, steps (C) to (E) illustrate production of amplified nucleic acid from the product of step (B). An RNA polymerase, such as T7 RNA polymerase, is used to generate multiple sense RNA transcripts (step (C)) to which the primer 24 can bind (step (D)) for primer extension. The dashed line in step (D) illustrates primer extension. The primer 24, sometimes referred to as a promoter primer, may be added prior to commencing amplification.

Between steps (C) to (F), the (-) strands are made available for hybridization to a promoter-primer 24. FIG. 2, steps (D) to (F) illustrate the use of a promoter-primer to form a double-stranded promoter which is recognized by an RNA polymerase and used to produce additional RNA transcripts. The produced transcripts may be used in another cycle of amplification (indicated by the arrow at the left of FIG. 2 connecting steps (F) and (C)). The steps of amplification are described in greater detail below under "Transcription-Associated Amplification."

FIGS. 3A through 3C illustrate the capture and detection of a target polynucleotide (c) with a labeled probe (d). At the beginning of the assay, the reagent mixture includes the immobilized probe (a) bound to a solid particle 10, the capture probe (b), the target polynucleotide (c), and the labeled probe (d) free in solution. As shown in FIG. 3A, in the first hybridization condition, a capture probe:target polynucleotide:labeled probe hybridization complex 30 is formed in solution. The capture probe (b) shown in FIG. 3A consists of a linker 31 joining a first base sequence recognition polynucleotide 33 and a second base sequence recognition polynucleotide 35. The first base sequence recognition polynucleotide 33 includes a target polynucleotide-binding region 32, and the second base sequence recognition polynucleotide 35 includes an immobilized probe-binding region 34.

As shown in FIG. 3B, in the second hybridization condition the capture probe:target polynucleotide:labeled probe hybridization complex 30 hybridizes to the immobilized probe (a), thereby producing an immobilized probe:capture probe:target polynucleotide:labeled probe complex 40 (*i.e.*, a bound labeled probe). This complex 40 is formed when the immobilized probe (a) hybridizes with the immobilized probe-binding region 34. The second hybridization condition may be achieved by lowering the temperature of the first hybridization condition.

Referring to FIG. 3C, a washing step may be used to remove unbound labeled probe (not shown) from the bound labeled probe (d) present in the complex 40 attached to the solid support 10. Detection of the bound labeled probe (d) is an indication of the initial presence of the target polynucleotide in the sample.

FIG. 4 illustrates an example of a solid support 10 to which are attached immobilized probes shown as T_{14} sequences. The upper immobilized probe (marked (a) at the right side) is shown in an

immobilized probe:capture probe complex in which the T₁₄ probe is hybridized (shown as ":" between bases) to a complementary A₁₄ sequence of a capture probe shown as

3' A₁₄TTTGTCACTAACCTTGATTCAAG 5' (SEQ ID NO:1). The middle immobilized probe

(marked (b) at the right side) is shown in an immobilized probe:capture probe:target polynucleotide

5 complex which contains the components of the immobilized probe:capture probe complex with the 5' region of the capture probe hybridized to a complementary target sequence shown as

5' CAGTCATTGGAACTAAGTAGTTC 3' (SEQ ID NO:2). The target sequence illustrated is an

internal sequence as indicated by terminal "NNNNNN" sequences. The lowest immobilized probe (marked (c) at the right side) is unhybridized.

10 Base Sequence Recognition Molecules

Base sequence recognition molecules contain sequence information that permits hybridization to sufficiently complementary nucleic acids in appropriate reaction conditions. By "sufficiently complementary" is meant a contiguous nucleic acid base sequence that is capable of hybridizing to a base sequence recognition molecule (e.g., another contiguous nucleic acid base sequence) by hydrogen bonding between complementary bases. The complementary base sequence may be complementary at each position in the base sequence recognition molecule using standard base pairing (e.g., G:C, A:T or A:U pairing). Alternatively, the complementary base sequence may contain one or more residues that are not complementary using standard hydrogen bonding (including abasic "nucleotides"), but the entire complementary base sequence is capable of specifically hybridizing with the base sequence recognition molecule in appropriate hybridization condition. For those skilled in the art, appropriate hybridization conditions are well known, can be predicted readily based on sequence composition, or can be determined empirically by using routine testing (e.g., See Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual*, 2nd ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989) at §§ 1.90-1.91, 7.37-7.57, 9.47-9.51 and 25 11.47-11.57 particularly at §§ 9.50-9.51, 11.12-11.13, 11.45-11.47 and 11.55-11.57). These base sequence recognition molecules may contain additional groups not providing sequence information. The additional groups, if present, do not prevent hybridization of a base sequence recognition molecule to a sufficiently complementary nucleic acid in the reaction conditions.

30 A base sequence recognition molecule comprises nucleotide base recognition groups joined together by a backbone. The nucleotide base recognition groups can hydrogen bond with nucleotide nitrogenous bases present in a nucleic acid. The backbone provides a proper conformation and spacing to allow the groups to hydrogen bond to nucleotides of a nucleic acid.

A given nucleotide base recognition group may be complementary to a particular nucleotide


(e.g., A, G, C, T, and U), and thus, be able to hydrogen bond with that nucleotide present in a nucleic acid. A nucleotide base recognition group may also be able to hydrogen bond with different nucleotides. For example, when inosine is a nucleotide base recognition group it can hydrogen bond with U, A, or C.

5 Preferred nucleotide base recognition groups are nitrogenous purine or pyrimidine bases, or derivatives thereof, which are able to hydrogen bond with either A, G, C, T, U or Inosine (I). Examples of base recognition groups include A, G, C, T, U, or I, and derivatives thereof. Examples of derivatives include modified purine or pyrimidine bases such as N⁴-methyl deoxyguanosine, deaza- or aza-purines and deaza- or aza-pyrimidines used in place of natural purine and pyrimidine 10 bases, pyrimidine bases having substituent groups at the 5 or 6 position, and purine bases having an altered or a replacement substituent at the 2, 6 or 8 positions. Such derivative and their synthesis are well known in the art (see, Cook, PCT Int'l Pub. No. WO 93/13121). Additional examples are 2-amino-6-methylaminopurine, O⁶-methylguanine, 4-thio-pyrimidines, 4-amino-pyrimidines, 4-dimethylhydrazine-pyrimidines, O⁴-alkyl-pyrimidines, and others known in the art.

15 The backbone of a base sequence recognition molecule may be made up of different groups or linkages known in the art. Preferably, the backbone contains one or more sugar-phosphodiester linkages, one or more peptide nucleic acid backbone groups, one or more phosphorothioate linkages, or combinations thereof.

20 Structure I illustrates a sugar-phosphodiester type backbone group where the sugar group is a pentofuranosyl group. The sugar groups are joined together by a phosphodiester linkage or other suitable linkage.

STRUCTURE I




25 Referring to Structure I, X represents the group joining two sugars. Examples of X include, -

$\text{P}(\text{O})_3$ -, $-\text{NHP}(\text{O})_3$ -, $-\text{OCOO}$ -, $-\text{OCH}_2\text{CONH}$ -, $-\text{OCH}_2\text{COO}$ - and $-\text{OCONH}$ -. As with the other examples provided herein, based on the disclosure provided, other equivalents well known in the art may also be used. Y_1 and Y_2 are independently selected groups. Examples of Y_1 and Y_2 include H, OH, an alkoxy containing up to 4 carbon atoms, halogen, and $\text{C}_1\text{-C}_4$ alkyl. Preferably, Y_1 and Y_2 are independently either H, OH, F, or OCH_3 . Base_1 and Base_2 are independently selected nucleotide base recognition groups. Preferably, Base_1 and Base_2 are independently either A, G, C, T, U or inosine (I). R_1 and R_2 represent independently selected groups which may include additional sugar-phosphodiester type groups, peptide nucleic acid, and moieties not providing sequence information such as abasic "nucleotides" (containing a phosphodiester backbone, but lacking a nucleotide base 5 recognition group), polymers such as polyethylene glycol, polysaccharides, polypeptides, peptides, and other non-nucleotide linkages. Other types of non-nucleotide linkers are well known (see Arnold 10 et al., U.S. Pat. No. 5,585,481).

Derivatives of Structure I that may be a component of a base sequence recognition molecule are known in the art such as molecules having a different type of sugar in the backbone. 15 For example, a base sequence recognition molecule may have cyclobutyl moieties connected by linking moieties, where the cyclobutyl moieties have heterocyclic bases attached thereto (e.g., see Cook et al., PCT Int'l Pub. No. WO 94/19023).

Another type of backbone of a base sequence recognition molecule is a peptide-type bond, 20 such as that present in peptide nucleic acid. "Peptide nucleic acid" refers to a DNA analogue where the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone as described previously (Hyrup & Nielsen, 1996, *Bioorg. & Med. Chem.* 4:5-23; Hydig-Hielsen et al., PCT Int'l Pub. No. WO 95/32305). Preferably, the peptide nucleic acid is made up of N-(2-aminoethyl)glycine 25 units as illustrated in Structure II, in which R_1 , R_2 , and Base_1 are as described for Structure I type compounds.

STRUCTURE II



Base sequence recognition molecules can be produced using known methods, such as standard organic synthesis methods for producing oligonucleotides and modified oligonucleotides (for example, see Eckstein, F., *Oligonucleotides and Analogues, a Practical Approach*, chapters 1-5, 1991; Caruthers *et al.*, *Meth. In Enzymol.*, vol. 154, p. 287, 1987; Bhatt, U.S. Pat. No. 5,252,723; 5 Klem *et al.*, PCT Int'l Pub. No. WO 92/07864; Cook, PCT Int'l Pub. No. WO 93/13121; Miller *et al.*, PCT Int'l Pub. No. WO 94/15619; McGee *et al.*, PCT Int'l Pub. No. WO 94/02051; Cook *et al.*, PCT Int'l Pub. No. WO 94/19023; Hyrup *et al.*, *Bioorg. Med. Chem.* 4:5-23, 1996; and Hydig-Hielsen *et al.*, PCT Int'l Pub. No. WO 95/32305; Ordoukhanian *et al.*, *Nuc. Acids Res.* 25(19):3783-3786, 1997; Myer *et al.*, *Bioconjug. Chem.* 7(4):401-412, 1996; Schultz *et al.*, *Nuc. Acids Res.* 24(15):2966-2973, 10 1996; Woo *et al.*, *Nuc. Acids Res.* 24(13):2470-2475, 1996; Agris *et al.*, *Biochimie* 77:125-134, 1995; Berressem *et al.*, *Nuc. Acids Res.* 23(17):3465-3472, 1995; Seela *et al.*, *Nuc. Acids Res.* 23(13):2499-2505, 1995; Vinayak *et al.*, *Nuc. Acids Symp. Ser.* 33:123-125, 1995; Limbach *et al.*, *Nuc. Acids Res.* 22(12):2183-2196, 1994; Gryaznov *et al.*, *Nuc. Acids Res.* 20(8):1879-1882, 1992; Kawana *et al.*, *Nuc. Acids Symp. Ser.* 25:93-94, 1991; Pfleiderer *et al.*, *Nuc. Acids Symp. Ser.* 15 24:29-32, 1991; Wagner *et al.*, *Nuc. Acids Res.* 19(21):5965-5971, 1991; Marquez *et al.*, *Nuc. Acids Symp. Ser.* 22:35-36, 1990; Lin *et al.*, *Nuc. Acids Res.* 17(24):10373-10383, 1989; Farrance *et al.*, *Anal. Biochem.* 179(1):60-65, 1989; Gildea *et al.*, *Nuc. Acids Res.* 17(6):2261-2281, 1989; Yeung *et al.*, *Nuc. Acids Res.* 16(10):4539-4554, 1988; Pon *et al.*, *Nuc. Acids Res.* 13(18):6447-6465, 1985; Millican *et al.*, *Nuc. Acids Res.* 12(19):7435-7453, 1984; Schinazi *et al.*, *J. Med. Chem.* 21(11):1141-20 1146, 1978).

Preferred base sequence recognition molecules independently include: (i) a backbone including at least one sugar-phosphodiester type group, at least one peptide nucleic acid group, at least one phosphorothioate group, or a combination thereof, and (ii) independently selected nucleotide base recognition groups able to hydrogen bond to A, G, C, T, U or I, joined to the backbone. Base sequence recognition molecules may include components selected which are deoxynucleotides, ribonucleotides, 2'-methoxy substituted ribonucleotides, or 2'-halo substituted ribonucleotides. Preferably, one or more of the referenced components make up at least about 70%, more preferably at least about 80%; still more preferably at least about 90%, and most preferably about 100% of the base sequence recognition molecule.

30 Immobilization to a Solid Support

A base sequence recognition molecule may be joined by various known means to different types of supports to form an immobilized probe. Covalent attachment of oligonucleotides synthesized using standard chemical techniques to a solid support has been described previously

(Lund, *et al.*, *Nuc. Acids Res.* 16:10861-10880, 1988; European Pat. App. Pub. No. 0444120).

Particularly preferred solid supports are magnetically attractable particles which are useful in a separation step because the particles can be attracted to a reaction container location and held in place while unbound solution components are washed away. Magnetically attractable particles can be produced using standard techniques or obtained from available commercial sources.

T_m and Hybridization Conditions

The methods of the present invention vary the hybridization conditions to control the timing of the formation of a capture probe:target complex and an immobilized probe:capture probe complex. The ability of two base sequence recognition molecules to hybridize depends upon the structures and the surrounding reaction environment. The reaction environment includes the composition of the solution containing two or more recognition molecules and the solution temperature.

Using a particular assay composition, a hybridization complex is not stable when the assay temperature is above the T_m of the complex. Solution factors well known in the art, such as salt concentration and the presence of denaturing agents, can affect the T_m of a given complex. Two base sequence recognition molecules making up a hybridization complex can be constructed to have T_m characteristics suitable for use in the present invention based on descriptions provided herein and techniques well known in the art (e.g., see Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual*, 2nd ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989) at §§ 1.90-1.91, 7.37-7.57, 9.47-9.51 and 11.47-11.57, particularly at §§ 9.50-9.51, 11.12-11.13, 11.45-11.47 and 11.55-11.57).

Hybridization complex stability is affected by the length and the degree of complementarity between two base sequence recognition molecules, the nucleotide base recognition groups, and the backbone of the base sequence recognition molecule. For example, the T_m of a complex formed between two base sequence recognition molecules can be lowered by constructing the molecules to have internal regions of less than 100% complementarity to each other. This may be achieved by including mismatches or linker components such as non-nucleotide linkers and abasic "nucleotides." Linker components may be positioned opposite a base in an opposing strand or can "bulge" out of a strand, thereby decreasing complex stability. The type of nucleotide base recognition groups which are present on opposing strands will also affect stability of a probe hybridization complex. For example, G:C pairing is stronger than A:T pairing, due to increased hydrogen bonding in G:C pairs compared to A:T pairs.

The backbone composition of a base sequence recognition molecule may be adjusted in

different ways to affect hybridization complex stability. Preferred backbones are peptide linkages such as those present in peptide nucleic acid, and sugar-phosphodiester type linkages such as those present in ribonucleic acids and deoxyribonucleic acids, or derivatives thereof. Peptide nucleic acids generally form a more stable complex with RNA than with the corresponding DNA sequence. More preferably, the backbone is made up of sugar-phosphodiester type linkages in which both the sugar group and the linkage joining the group can affect complex stability. For example, the sugar effect can be demonstrated with 2'-methoxy substituted RNA groups, in which a hybridization complex formed between 2'-methoxy substituted RNA and the complementary 2' OH RNA is generally more stable than a corresponding DNA:RNA complex. A 2'-fluoro substituted RNA has essentially the same type of effect as 2'-methoxy substituted RNA on complex stability.

10 A linkage joining two sugar groups may affect hybridization complex stability by affecting the overall charge or the charge density, or by affecting steric association between two molecular components. Steric interactions from bulky linkages produce "bulges" that reduce complex stability. Linkages with charged (e.g., phosphorothioates) or neutral (e.g., methylphosphonates) groups can 15 affect complex stability.

15 T_m can be predicted using standard calculations and measured using routine testing techniques well known in the art. Such methods are described, for example, in Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual*, 2nd ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989) at §§ 1.90-1.91, 7.37-7.57, 9.47-9.51 and 11.47-11.57, particularly at §§ 9.50-9.51, 11.12-11.13, 11.45-11.47 and 11.55-11.57), and Hogan *et al.*, U.S. Pat. No. 5,547,842.

20 In the first hybridization solution of preferred embodiments of the present invention, the T_m of the capture probe:target polynucleotide complex is greater than the T_m of the immobilized probe:capture probe complex by at least about 5 °C, more preferably, by at least about 10 °C, even more preferably, by at least about 20 °C, and most preferable by at least about 25 °C.

25 Changing the Hybridization Conditions

30 The preferred method of changing the hybridization conditions is by changing the temperature of the hybridization solution containing assay components. Changes in temperature may readily be achieved without adding reagents to the solution and, thus, are more compatible with automation. An automated assay is a preferred embodiment of the present invention. Preferably, the second hybridization condition is achieved by lowering the temperature of the first hybridization condition by at least about 10 °C, more preferably by at least 15 °C, still more preferably by at least about 20 °C, and most preferably by at least about 25 °C. However, any known method of lowering the stringency of a hybridization condition such as by increasing the ionic strength of the solution or

diluting the solution with denaturants may be used to achieve the second hybridization condition.

Amplification

Amplification increases the number of copies of the target polynucleotide. Amplification conditions are compatible with nucleic acid polymerization to produce a nucleic acid strand complementary to a nucleic acid template by using at least one nucleic acid polymerase. 5 Amplification conditions include one or more enzymes, amplification oligonucleotides, nucleoside triphosphate substrates, buffers, and incubation at an appropriate temperature. The specific conditions are well known in art and depend upon the type of nucleic acid amplification used.

Enzymes.

10 Suitable nucleic acid polymerases for carrying out nucleic acid amplification procedures are readily available commercially or can be isolated and purified. Such polymerases include, for example, DNA-dependent DNA polymerases such as *Escherichia coli* DNA polymerase I, *Bacillus stearothermophilus* DNA polymerase I, *B. caldotenex* DNA polymerase I, T4 DNA polymerase, and *Taq* polymerase. Other suitable enzymes are DNA-dependent RNA polymerases such as, for 15 example, T7 RNA polymerase, T3 RNA polymerase, and SP6 RNA polymerase. Suitable enzymes also include RNA-dependent DNA polymerases such as, for example, avian myeloblastosis virus (AMV) reverse transcriptase and Moloney murine leukemia virus (MMLV) reverse transcriptase. Amplification may also be accomplished using replicases (e.g., Q β -replicase), ligases (e.g., *E. coli* DNA ligase and T4 DNA ligase), or combinations of enzymes.

20 Amplification Oligonucleotides

"Amplification oligonucleotides" are oligonucleotides which hybridize to a target nucleic acid, or its complement, and participate in an amplification reaction. Examples of amplification oligonucleotides include primers and promoter-primers.

25 The selection of amplification oligonucleotides depends upon the amplification method used and the nucleic acid being amplified. A particular amplification oligonucleotide may be readily designed and synthesized by one skilled in the art depending on the sequence of the desired target nucleic acid and the amplification method chosen by the practitioner of the present invention. Examples of commonly used amplification oligonucleotides include those which are analogous or 30 complementary to a nucleotide base sequence and which may optionally contain nucleic acid sequence regions that are not complementary to the target nucleic acid. For example, an amplification oligonucleotide may contain a promoter sequence recognized by an RNA polymerase, or a base sequence recognized by a replicase.

An analogous amplification oligonucleotide includes a region capable of hybridizing to a

nucleic acid that is perfectly complementary to a region of the target nucleic acid (e.g., a cDNA when the target nucleic acid is an RNA). The analogous oligonucleotide may hybridize to the complementary nucleic acid at a position located near the 3' end of the complementary target sequence. The analogous oligonucleotide may also contain a non-complementary region, such as a 5 promoter sequence region, and/or one or more modifications, such as a modification that inhibits nucleic acid polymerase activity. Preferably, the analogous oligonucleotide contains at least about 10 contiguous bases, and more preferably at least about 12 contiguous bases, which are complementary to the nucleic acid that is perfectly complementary to a region of the target nucleic acid. The contiguous bases are preferably at least about 80%, more preferably at least about 90%, and most preferably about 100% complementary to a region of the target nucleic acid sequence. 10 The analogous oligonucleotide is preferably about 12 to 60 nucleotide bases in length and may optionally include modified nucleotide bases.

A template-complementary amplification oligonucleotide has a region capable of hybridizing to the target nucleic acid at a position located 3' of the target sequence. The template-complementary oligonucleotide may contain a non-complementary region such as a 5' promoter region. Preferably, the target-complementary oligonucleotide contains at least about 10 contiguous bases, and more preferably at least about 12 contiguous bases, which are complementary to a 15 region of the target nucleic acid sequence. The contiguous bases are preferably at least about 80%, more preferably at least about 90%, and most preferably about 100% complementary to a region of the target sequence. The template-complementary oligonucleotide is preferably 12 to 60 bases long and optionally may include modified nucleotides.

A "primer" refers to an optionally modified oligonucleotide which is capable of hybridizing to a template and which has a 3' end that can be efficiently extended in a known polymerization reaction. The 5' region of the primer may be non-complementary to the target nucleic acid. If the 5' 20 non-complementary region includes a promoter sequence, it is referred to as a "promoter-primer." A primer or promoter-primer may be analogous or complementary to a target nucleic acid.

Transcription-Associated Amplification

Transcription-associated amplification uses an RNA polymerase to produce multiple RNA transcripts from a nucleic acid template. Transcription-associated amplification generally employs 25 an RNA polymerase, a DNA polymerase, deoxyribonucleoside triphosphates, ribonucleoside triphosphates, and a promoter-template complementary oligonucleotide. Often an analogous oligonucleotide is also used.

Different variations of transcription-associated amplification are well known in the art.

Examples of different variations, which use different reaction conditions and different numbers and types of amplification oligonucleotides, are described in detail in Burg *et al.*, U.S. Pat. No. 5,437,990; Kacian *et al.*, U.S. Pat. Nos. 5,399,491 and 5,554,516; Kacian *et al.*, PCT Int'l Pub. No. WO 93/22461; Gingeras *et al.*, PCT Int'l Pub. No. WO 88/01302; Gingeras *et al.*, PCT Int'l Pub. No. WO 88/10315; Malek *et al.*, U.S. Pat. No. 5,130,238; Urdea *et al.*, U.S. Pat. Nos. 4,868,105 and 5,124,246; McDonough *et al.*, PCT Int'l Pub. No. WO 94/03472; and Ryder *et al.*, PCT Int'l Pub. No. WO 95/03430.

Briefly, generally transcription-associated amplification uses a promoter-template complementary oligonucleotide containing a 5' base sequence region which, when made double-stranded, is recognized by an RNA polymerase (labeled "P" in FIG. 2), and a 3' sequence region capable of hybridizing to a template nucleic acid at a location 3' of a target sequence (as shown in FIG. 2, step (A)). After hybridization of the promoter-template complementary oligonucleotide and the template, a double-stranded promoter is formed upstream from the template. The double-stranded promoter may be formed by polymerase-mediated primer extension of the promoter-template complementary oligonucleotide to produce a target complementary strand (see FIG. 2, step (A)), followed by hybridization of an analogous oligonucleotide (e.g., primer 24 of FIG. 2, step (B)) and primer extension of the analogous oligonucleotide (see FIG. 2, step (B)). Other known techniques are suitable for forming a double-stranded promoter, such as those involving primer extension of the target nucleic acid.

Transcription-associated amplification proceeds with the binding of an enzyme having RNA polymerase activity to a promoter region and synthesis of single-stranded RNA transcripts in a 5' to 3' direction (see FIG. 2, step (C)). Multiple RNA transcripts (e.g., about 100 to 3,000), can be produced by transcription-associated amplification using a single template (e.g., by repeating FIG. 2, steps (C) to (F)).

In a preferred embodiment of the present invention, a transcription-associated amplification procedure that uses RNase H activity is used for target amplification. This generates large amounts of single-stranded amplified nucleic acid in an essentially constant reaction condition. More preferably, the RNase H activity is supplied by a reverse transcriptase.

Other Amplification Methods

Other well-known amplification procedures may be used in the amplification step of the methods of the present invention, including Replicase-Mediated Amplification, Polymerase Chain Reaction (PCR), and Ligase Chain Reaction (LCR). Replicase-mediated amplification uses self-replicating RNA molecules, and a replicase such as QB-replicase (e.g., see Kramer *et al.*, U.S. Pat.

No. 4,786,600; PCT Int'l Pub. No. WO 90/14439). PCR amplification is well known and uses DNA polymerase, primers and thermal cycling to synthesize multiple copies of the two complementary strands of a DNA or cDNA (e.g., *see* Mullis *et al.*, U.S. Pat.s No. 4,683,195, 4,683,202, and 4,800,159; *Methods in Enzymology*, 1987, Vol. 155:335-350). LCR uses at least four separate 5 oligonucleotides to amplify a target and its complementary strand by using multiple cycles of hybridization, ligation, and denaturation (see European Pat. App. Pub. No. 0 320 308).

Detection of Target Polynucleotide

The presence of a target polynucleotide can be detected using different techniques that use a detection probe and/or detect an amplified nucleic acid. Preferably, the target polynucleotide is 10 detected using a labeled probe which hybridizes to the target polynucleotide or to an amplification product of the target polynucleotide, particularly an amplified nucleic acid that is complementary to the target polynucleotide.

Labeled probes may contain different types of labels and different techniques may be used to detect the label. For example, well known probe labels include radioisotopes, fluorescent 15 moieties, chemiluminescent moieties, and catalytic groups (e.g., an enzyme which participates in a reaction resulting in a color change). Examples of production and/or use of such labeled probes are described in detail in Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual*, 2nd ed. (Cold Spring Harbor Laboratory Press, Cold Spring Habor, NY, 1989), Chapter 10; Nelson *et al.*, U.S. Pat. No. 5,658,737; Woodhead *et al.*, U.S. Pat. No. 5,656,207; Hogan *et al.*, U.S. Pat. No. 5,547,842; Arnold 20 *et al.*, U.S. Pat. No. 5,283,174; Kourilsky *et al.*, U.S. Pat.. No. 4,581,333; and Becker *et al.*, European Pat. App. Pub. No. 0 747 706.

Labeled probes may be hybridized to a target polynucleotide, an amplified nucleic acid, or an intermediate molecule which is hybridized directly or indirectly to the target polynucleotide or 25 amplified nucleic acid. Indirect hybridization may be accomplished by using multiple intermediate molecules hybridized together.

Amplified nucleic acid may be detected using a labeled probe or using other well known methods of detecting nucleic acid. For example, the amplified nucleic acid may be labeled during amplification by using labeled precursors or after amplification using fluorescent intercalating agents (e.g., ethidium bromide). Labeled amplified nucleic acid may be detected using well known 30 procedures, such as, for example, gel filtration, gel electrophoresis, and HPLC.

The following examples illustrate some preferred embodiments of the present invention, although those skilled in the art will appreciate that other reagents and reaction conditions may be used to equally practice the methods of the present invention.

Example 1: Adjusting T_m by Varying Complementarity Length

One method of adjusting the T_m of a hybridization complex is to vary the length of complementarity between two nucleic acids making up the complex. This example illustrates changes in T_m due to differences in the lengths of complementarity in a complex.

5 Hybrids were formed between a first and second oligonucleotide strands. The first strand was a homopolymer of 40 deoxythymidines (dT_{40}), and the second strand was a homopolymer of deoxyadenosines of varying sizes (dA_n). These oligonucleotides were synthesized using standard nucleic acid synthesis procedures.

10 Both strands (350 pmols each) were mixed in a 40 μ L volume containing 20 μ L of 2X Hybridization Buffer (200 mM lithium succinate (pH 5.1-5.2), 17% lithium lauryl sulfate (LLS), 3 mM ethylenediaminetetraacetic acid (EDTA), and 3 mM ethylene glycol N, N, N', N'-tetraacetic acid (EGTA)) and heated at 55 $^{\circ}$ C for 30 minutes. Then, each complex was diluted to 300 μ l with 1X Hybridization Buffer (*i.e.*, half the concentration of 2X Hybridization Buffer).

15 In this solution, T_m was determined by detecting a hyperchromatic shift. Briefly, absorbance was measured at 260 nm during incremental changes in the temperature of the reaction mixture and a shift in the absorbance of the solution was detected over the temperature range. The T_m is the temperature at the midpoint of the absorbance shift. Table 1 shows the results of hybridization complexes in which the dA_n length varied over a range of dA_{10} to dA_{40} .

20

Table 1

Hybrid	T_m
$dA_{40} : dT_{40}$	70.3 $^{\circ}$ C
$dA_{30} : dT_{40}$	68.4 $^{\circ}$ C
$dA_{25} : dT_{40}$	64.5 $^{\circ}$ C
$dA_{20} : dT_{40}$	61.5 $^{\circ}$ C
$dA_{15} : dT_{40}$	56.0 $^{\circ}$ C
$dA_{10} : dT_{40}$	50.4 $^{\circ}$ C

25 As seen from these results, as the length of complementarity increased, the T_m of the complex also increased. The longer hybridization complexes (*e.g.*, $dA_{30} : dT_{40}$) tended to have relatively broad absorbance shifts because there are potentially many types of hybridization complexes in the mixture due to offset pairing (*e.g.*, 30-mer, 29-mer, 28-mer pairing and so forth).

The combinations of homopolymers that resulted in shorter hybridization complexes (e.g., dA₁₅ : dT₄₀ which can form up to a 15-mer complex) had a T_m below about 60°C.

This property was further examined by incubating 100 µg of immobilized poly-dT₁₄ or dT₃₀ probe attached to magnetic beads with 2.5 pmols of a ³²P-labeled dA₃₀ capture probe in solution.

5 Reactants were incubated in a hybridization buffer (3 mM EDTA, 3 mM EGTA, 17% LLS, 190 mM succinic acid, 250 mM lithium hydroxide, pH 5.1 ± 0.1) for 30 min at either 60°C or room temperature (about 25°C) in five replicates for each hybridization condition. At room temperature, the average percentages of the labeled dA₃₀ probes hybridized to the dT₁₄ and dT₃₀ probes were 90% and 88%, respectively, whereas at 60°C the average percentages of the labeled dA₃₀ probes hybridized to the dT₁₄ and dT₃₀ probes were 61% and 1%, respectively.

10

These hybridization characteristics were exploited in a two-step hybridization assay in which the immobilized probe was present during hybridization conditions at two different temperatures as demonstrated in the next example.

Example 2: Two Step Hybridization

15 This example illustrates the two-step hybridization method using two hybridization temperatures to achieve target polynucleotide capture. In one assay condition, the capture probe, target polynucleotide and immobilized probe were concurrently in the admixture throughout both hybridization conditions. In another assay, the immobilized probe was added after hybridization of the capture probe to the target polynucleotide in the first hybridization condition. The concurrent admixture of the first assay is advantageous because it requires fewer reagent addition steps, but the separate addition of immobilized probe generally resulted in about a two-fold higher signal than seen for the two-step hybridization performed with the concurrent admixture.

20

The capture probe oligonucleotide and acridinium ester (AE)-labeled target polynucleotide were synthesized and detected using standard techniques. Such techniques are known in the art, 25 as described in Sambrook et al., *Molecular Cloning, A Laboratory Manual*, 2nd ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), Chapter 10; Nelson et al., U.S. Pat. No. 5,658,737; Woodhead et al., U.S. Pat. No. 5,656,207; Hogan et al., U.S. Pat. No. 5,547,842; and Arnold et al., U.S. Pat. No. 5,283,174.

20 Capture probe (1.25 pmol) and AE-labeled target polynucleotide were initially incubated for 30 min at 60°C in 1X Hybridization Buffer (see Example 1) with, or without, 100 µg of a poly-T immobilized probe attached to Seradyn magnetic beads, and then shifted to room temperature for 30 min. For samples incubated at 60°C without the bead-attached immobilized probe, this component (in 50 µl 1X Hybridization Buffer) was added at the start of the second incubation.

Volumes of both samples were kept the same by adding 50 μ l 1X Hybridization Buffer to the assay that already contained immobilized probe. The immobilized probe was a homopolymer of dT₁₄ or dT₃₀ attached to the solid support which were magnetic beads. The capture probe was a polynucleotide had a base sequence complementary to a sequence in the target polynucleotide (a 5 *Neisseria gonorrhoeae* 16S rRNA sequence) and a poly-A tail of dA₁₅ or dA₃₀. The target sequence was AE-labeled *N. gonorrhoeae* 16S rRNA. Using this combination, an immobilized probe:capture probe:target polynucleotide complex was formed by hybridization of target sequence with the target complementary sequence of the capture probe during the first hybridization at 60°C, and hybridization of the dA region of the capture probe with the dT region of the immobilized probe 10 during the second hybridization at room temperature.

The captured AE-labeled target polynucleotide was purified by applying a magnetic field to attract the beads with immobilized probe to a location on the reaction container, and then washing twice with Binding Buffer (50 mM lithium succinate, 100 mM LiCl, 1.5% LLS, 1.5 mM EDTA, 1.5 mM EGTA, pH 5.2). The beads were resuspended and captured target polynucleotide was detected by 15 measuring chemiluminescence produced from the AE label. Chemiluminescence was detected as Relative Light Units (RLU) using techniques substantially as described previously (Arnold *et al.* *Clinical Chemistry* 35:1588-1594 (1989); Nelson *et al.*, U.S. Pat. No. 5,658,737. The RLU results are presented in Table 2 are mean values of samples tested in triplicate.

Table 2

20	Poly - T of Immobilized Probe	Poly - A of Capture Probe	Immobilized Probe Added Before Second Hybridization	Immobilized Probe Present During Both Hybridizations
	dT ₃₀	dA ₃₀ dA ₁₅	54,895 ¹ 44,558	31,608 30,290
	dT ₁₄	dA ₃₀ dA ₁₅	65,313 ² 43,285	63,240 37,479

¹ Represents capture of 62% of the labeled target.
25 ² Represents capture of 67% of the labeled target.

The results of Table 2 show that a two step hybridization can be used to effectively capture the target polynucleotide using a capture probe and an immobilized probe which is either present in the reaction mixture during both hybridizations or added before the second hybridization. Thus, this method can achieve target capture when all reagents are concurrently present during both 30 hybridizations, thus requiring fewer reagent addition steps. The results of Table 2 also show that relatively short complementary sequences (dT₁₄ and dA₁₅) were effective for target capture in the

immobilized probe:capture probe:target polynucleotide complex. Use of the 14-mer immobilized probe resulted in substantially the same signal whether the immobilized probe was added at the second hybridization or was present during both hybridizations. A shorter immobilized probe homopolymer appeared to be more advantageous than a shorter capture probe homopolymer as seen by the higher signal obtained with the dT₁₄:dA₃₀ combination compared to the dT₃₀:dA₁₅ combination.

Example 3: Two Step Hybridization With Amplified Target Sequence

This example shows that the two step hybridization method of the present invention can be used to detect a *Mycobacterium tuberculosis* target polynucleotide present in a clinical sample. The assay is also capable of detecting other *Mycobacterium* species (i.e., *M. bovis*, *M. simiae* and *M. africanum*, often referred to collectively as the *M. tuberculosis* complex) but, for the sake of simplicity, will be described herein with reference to *M. tuberculosis*.

The basic protocol included the following steps. A lysate of the sample was prepared by adding a clinical sample (e.g., 500 μ l of sediment from sputum, bronchoalveolar lavage or bronchial washings) to an equal volume of a lysis buffer (2.2 M LiCl, 250 mM HEPES buffer, pH 7.5, containing 4% (w/v) LLS) and organisms in the lysate were heat killed (95 °C for 15 min). If *M. tuberculosis* is present in the clinical sample, a target polynucleotide (e.g., rRNA sequence) derived from *M. tuberculosis* will be present in the lysate. An aliquot (250 μ l) of the lysate was mixed with an equal volume of a solution containing the capture probe specific for the *M. tuberculosis* target sequence and an immobilized probe attached to a solid support. The capture probe was a 58-base oligonucleotide containing a 5' 15-base sequence complementary to a *M. tuberculosis* rRNA sequence, an internal T₃, and a 3' dA₄₀ tail. The immobilized probe was a poly-dT₁₄ sequence attached using carbodiimide chemistry (substantially as previously described by Lund, et al., *Nuc. Acids Res.* 16:10861-10880, 1988) to a solid support of magnetic particles (0.7-1.05 μ particles, Seradyn, Indianapolis, IN). In this assay, 5 pmol of the capture probe and 50 μ g of immobilized probe particles were used per reaction. The mixture was incubated successively at two different temperatures (60 °C for 20 min, and 25 °C for 15 min). At the first temperature, the *M. tuberculosis*-complementary sequence of the capture probe hybridized to the target sequence because the T_m of that hybridization complex is greater than 60 °C, and at the second temperature the homopolymeric immobilized probe hybridized to the complementary homopolymeric region of the capture probe because the T_m of the dA:dT complex is less than about 50 °C. Following both incubations, the magnetic beads were separated from the solution using a magnetic field substantially as described in Example 2. If *M. tuberculosis* was present in the sample, these magnetic beads have attached a

hybridization complex consisting of immobilized probe:capture probe:target polynucleotide. If *M. tuberculosis* was not present in the sample, the beads have attached a hybridization complex consisting of immobilized probe and capture probe. The beads were washed twice with 1 ml of washing buffer per wash by resuspending the beads in buffer and then repeating the magnetic separation step. Washed beads were then resuspended in 75 μ l of a nucleic acid amplification reagent solution for transcription associated amplification using methods substantially as described in Kacian *et al.*, U.S. Pat. Nos. 5,399,491 and 5,554,516. The beads and 15 pmol of each primer specific for the *M. tuberculosis* target polynucleotide were incubated in a reaction mixture (40 mM Trizma base, pH 7.5, 17.5 mM KCl, 20 mM MgCl₂, 5% polyvinylpyrrolidone (PVP), 1 mM each dNTP, 4 mM each rNTP), covered with a layer (200 μ l) of inert oil to prevent evaporation, at 60 °C for 10-15 min, and then at 41.5-42 °C for 5 min. Reverse transcriptase (about 750 Units and about 2,000 Units of T7 RNA polymerase in 25 μ l) was added per reaction, mixed, and the amplification of the target polynucleotide proceeded at 41.5-42 °C for 2 hr. Amplified *M. tuberculosis* target sequences were detected using an AE-labeled probe which was detected as chemiluminescence and expressed in relative light units (RLU) substantially as described previously (U.S. Pat. No. 5,658,737 at column 25, lines 27-46; Nelson *et al.*, 1996, *Biochem.* 35:8429-8438 at 8432). For each assay, a negative control consisting of all of the same reagents but substituting an equal volume of negative sputum for sample, and a positive control consisting of all of the same reagents but including 50 μ l of extracted total cellular *M. tuberculosis* RNA (containing about 2000 copies of rRNA) instead of sample. Samples were tested in duplicate for each assay (RLU No.1 and RLU No.2 in Table 3).

The results of this assay on fifteen clinical samples that were independently determined to be positive for presence of *M. tuberculosis* (based on standard clinical smear analysis and/or BACTEC broth culture results) are presented in Table 3.

Table 3

Sample No.	Smear Result	Culture Result	RLU No. 1	RLU No. 2
1	Positive	Unknown	3.04×10^6	2.87×10^6
2	Positive	Unknown	3.09×10^6	2.99×10^6
3	Positive	Unknown	3.18×10^6	3.00×10^6
4	Positive	Unknown	3.28×10^6	3.23×10^6
5	Positive	Positive	2.97×10^6	3.04×10^6
6	Positive	Positive	3.16×10^6	2.94×10^6
7	Unknown	Positive	2.87×10^6	2.98×10^6
8	Negative	Positive	3.46×10^4	2.05×10^6
9	Negative	Positive	3.11×10^6	2.99×10^6
10	Negative	Positive	3.09×10^6	3.09×10^6
11	Negative	Positive	1.35×10^6	6.15×10^5
12	Negative	Positive	3.01×10^6	3.13×10^6
13	Negative	Positive	2.90×10^6	2.88×10^6
14	Negative	Positive	3.12×10^6	3.07×10^6
15	Negative	Positive	2.93×10^6	3.00×10^6
Positive Controls	Not Applicable	Not Applicable	2.98×10^6	2.89×10^6
Negative Controls	Not Applicable	Not Applicable	3.45×10^3	5.67×10^3

20

As can be seen from the results shown in Table 3, all of the samples that were positive for *M. tuberculosis* based on at least one clinical assay result, tested positive in the two step hybridization assay relative to the negative control. Positive results were based on samples having an RLU reading of at least about 10-fold greater than that of the negative control. For most samples, the positive result was based an RLU reading of at least about 100-fold greater than that of the negative control. Generally, the chemiluminescence indicative of *M. tuberculosis* target polynucleotide in the sample was about 1,000-fold greater than that detected in the negative control and essentially equal to or greater than that of the positive control.

Example 4: Two Step Hybridization Assay for Detecting Varying Levels of a *Neisseria gonorrhoeae*

30

Target

This example shows that the two-step hybridization method of the present invention can be used to detect as little as 5 fg of a target polynucleotide indicative of a bacterial infection. The target polynucleotide was a rRNA sequence specific to *N. gonorrhoeae* (Hogan *et al.*, U.S. Pat. No. 5,541,308; Nelson *et al.*, 1996, *Biochem.* 35:8429-8438). Moreover, the results were reproducible with little variation when the samples were stored over a three-day period at 0-4°C and assayed on

35

day 1, 2 and 3. The 5 fg and 50 fg amounts of *N. gonorrhoeae* target polynucleotide assayed correspond to rRNA present in 1 cell and 10 cells, respectively.

The basic protocol used includes the following steps. For each assayed sample, a 20 μ l aqueous solution of either 0 fg (negative control), 5 fg or 50 fg of *N. gonorrhoeae* target 5 polynucleotide in 400 μ l of water was mixed with 400 μ l of a synthetic urine control (KOVATROLTM; Hycor Biomedical, Inc.) and 200 μ l of a target capture buffer (TCB; consisting of 2.2 M LiCl, 250 mM HEPES buffer, pH 7.5) containing a capture oligonucleotide (6.25 nM) having a sequence complementary to the *N. gonorrhoeae* target polynucleotide and a dT₃dA₃₀ sequence. Immobilized dT₁₄ probe attached to magnetic particles as the solid support were added to 100 μ g/ml and the 10 mixture was incubated successively at two different temperatures (60 °C for 20 min, and 25 °C for 15 min). At the first temperature, the capture probe and the target polynucleotide hybridized because the T_m of the capture probe:target polynucleotide complex is greater than 60 °, and at the second temperature the immobilized probe and the poly-dA portion of the capture probe hybridized because the T_m of the dA:dT complex is less than about 52 °C. Following incubation, the magnetic beads 15 were separated from the solution using a magnetic field substantially as described in Example 2. For samples containing the *N. gonorrhoeae* target polynucleotide, the magnetic beads have attached the immobilized probe:capture probe:target polynucleotide complex, whereas for the negative control sample the beads have attached the immobilized probe:capture probe. Then the beads were washed twice substantially as described in Example 3 and the washed beads were 20 resuspended in 75 μ l of a nucleic acid amplification reagent and amplified substantially as described in Example 3 using a primer specific for the *N. gonorrhoeae* target polynucleotide. After amplification, the amplified target sequences were detected using a AE-labeled probe which was detected using a chemiluminescent assay as described in Example 3, and the signal was expressed in relative light units (RLU). For each day's assays, background RLU of the negative controls and 25 positive controls were determined in the same manner using the same reagents. Results of the assays are shown in Table 4, including RLU results for each experimental sample, and the mean values of two positive controls and ten negative controls obtained for each day. The background (mean of two samples) values were 6.81 \times 10², 1.18 \times 10³ and 6.61 \times 10² RLU for days 1, 2 and 3 respectively.

Table 4

Sample	Target (fg)	Day 1 RLU	Day 2 RLU	Day 3 RLU
1	5	7.78×10^5	6.46×10^5	6.95×10^5
2	5	7.73×10^5	7.08×10^5	7.06×10^5
3	5	8.30×10^5	7.00×10^5	6.57×10^5
4	5	7.69×10^5	7.34×10^5	7.60×10^5
5	5	7.73×10^5	7.76×10^5	7.95×10^5
6	5	7.01×10^5	6.47×10^5	7.14×10^5
7	5	7.32×10^5	6.70×10^5	7.63×10^5
8	5	7.84×10^5	7.23×10^5	7.06×10^5
9	5	7.45×10^5	7.17×10^5	7.18×10^5
10	5	7.45×10^5	7.11×10^5	7.68×10^5
11	50	8.58×10^5	7.51×10^5	7.57×10^5
12	50	8.20×10^5	4.61×10^5	7.77×10^5
13	50	7.66×10^5	6.99×10^5	7.21×10^5
14	50	7.85×10^5	7.97×10^5	7.45×10^5
15	50	8.17×10^5	7.80×10^5	7.76×10^5
16	50	7.98×10^5	7.33×10^5	7.42×10^5
17	50	7.51×10^5	7.36×10^5	7.41×10^5
18	50	7.76×10^5	8.01×10^5	7.80×10^5
19	50	7.24×10^5	7.27×10^5	7.62×10^5
20	50	7.74×10^5	7.54×10^5	7.70×10^5
Negatives (10)		201 range: 167-284	-218 range: 0 to -578	74 range: 0 to 148

25 The results presented in Table 4 show that the two step hybridization assay is capable of reproducibly detecting as little as 5 fg of an *N. gonorrhoeae* target polynucleotide, producing chemiluminescence significantly above that of a samples containing no target polynucleotide tested under the same conditions. Moreover, when samples were stored and retested using the method over the course of three days there was good reproducibility of the results over the entire time 30 period. The results also show good sample-to-sample reproducibility over the three-day period.

Example 5: Two-Step Hybridization Assay for Detecting Bacterial In Clinical Urine Samples

This example shows that the two-step hybridization method of the present invention can be used to detect a target indicative of a bacterial infection using clinical urine samples. The target polynucleotide was a sequence specific to *Chlamydia trachomatis*. The samples had been

5 independently tested for *C. trachomatis* using a PCR-based assay and the results obtained with the two-step hybridization method were compared to those obtained with the PCR-based assay. The urine samples were tested in duplicate using the two-step hybridization method, with the samples arranged in a random order relative to their classification (positive or negative) based on their PCR-based assay results.

10 Briefly, the two-step hybridization assay protocol was as follows. Each reaction tube contained 200 μ l of TCB (as defined in Example 4) containing 6.25 pmols of a capture oligonucleotide having a sequence complementary to the *C. trachomatis* target polynucleotide and a dT₃dA₃₀ sequence, into which was added 800 μ l of prepared urine sample (400 μ l urine plus 400 μ l TM buffer (100 mM (NH₄)₂SO₄, 50 mM Hepes, pH 7.5, 8% LLS)) or 800 μ l of controls (negative

15 controls were 400 μ l KOVATROL™ plus 400 μ l TM buffer; positive controls were 400 μ l KOVATROL™ plus 400 μ l TM buffer containing 5 fg of a *C. trachomatis* total cellular RNA (i.e., rRNA target polynucleotide). The tubes were sealed, mixed, and incubated at 60 °C for 30 min, and then at 40 °C for 30 min. The tubes were then subjected to a magnetic field and the magnetic

beads with immobilized probe were separated from the solution, and the immobilized components 20 were washed twice substantially as described in Example 2. At 60 °C, the capture probe and the *C. trachomatis* target polynucleotide hybridized because the T_m of the capture probe:target polynucleotide complex is greater than 60 °C, and at the second temperature the immobilized poly-dT probe and the poly-A portion of the capture probe hybridized because the T_m of the dA:dT complex is less than about 52 °C. The target polynucleotide was amplified using a primer specific 25 for the *C. trachomatis* target sequence and reagents for transcription-associated amplification contained in a volume of 75 μ l substantially as described in Example 3 except that amplification was for 1 hr. The AE-labeled probe specific for the *C. trachomatis* target sequence was added (in 100 μ l), mixed, and the mixture incubated at 60 °C for 20 min, after which 300 μ l of the selection reagent

was added, mixed, incubated and detected as RLU (see Example 3).

30 Table 5 shows the results of the two-step hybridization assays ("RLU" is the mean of the duplicate tests for 30 urine samples, and the means of the five positive and five negative controls) and the PCR-based tests (positive or negative for detection of *C. trachomatis* nucleic acid).

Table 5

Sample No.	PCR Results	RLU	Sample No.	PCR Results	RLU
1	Positive	4.42×10^5	17	Negative	0
2	Negative	1.66×10^3	18	Positive	3.59×10^5
3	Positive	2.95×10^5	19	Positive	3.64×10^5
4	Negative	0	20	Positive	3.51×10^5
5	Positive	1.62×10^5	21	Positive	3.75×10^5
10	Positive	4.15×10^5	22	Negative	9.15×10^3
7	Positive	5.76×10^5	23	Positive	3.21×10^5
8	Negative	3.69×10^3	24	Negative	0
9	Positive	4.45×10^5	25	Positive	4.59×10^5
10	Negative	0	26	Negative	8
11	Positive	5.00×10^5	27	Positive	3.07×10^5
12	Negative	0	28	Positive	3.52×10^5
15	Negative	0	29	Negative	0
13	Negative	0	30	Negative	0
14	Negative	0	Positive Controls	Not Applicable	3.14×10^5
15	Negative	0			
16	Negative	0	Negative Controls	Not Applicable	0

20 As can be seen from the results of Table 5, in all samples assayed, the two-step hybridization method provided positive results for those samples that had independently tested positive using a PCR-based assay, and in all cases that tested negative using the PCR-based assay, the sample was also negative when assayed by the two-step hybridization method. For those negative samples that had relatively high (10^3) negative signal (samples 2, 8 and 22), the 25 duplicate assays always included one "0" RLU signal and one relatively high background signal. Thus, the two-step hybridization assay can be used to detect bacteria present in clinical urine samples, and provide positive or negative results comparable to those obtained in a PCR assay.

Example 6: Two Step Hybridization Assay for Detecting Multiple Bacterial Targets in A Sample

30 This example shows that the two-step hybridization method of the present invention can be used to detect multiple targets indicative of bacterial infections by different species in a single

sample. The target polynucleotides were sequences specific to *Neisseria gonorrhoeae* and *Chlamydia trachomatis* and the assays were performed substantially as described in Examples 3-6. These samples were also spiked with a contaminant (1% to 10% v/v blood).

The assays were performed substantially as described in Examples 3-6, where the samples 5 consisted of normal urine (no bacterial contamination) that contained either: no target polynucleotide (negative controls); 5 fg of a *C. trachomatis* target polynucleotide; 5 fg of a *N. gonorrhoeae* target polynucleotide; or a mixture of 5 fg of a *C. trachomatis* target polynucleotide and 5 fg of a *N. gonorrhoeae* target polynucleotide. For each set of samples, the assay tubes further included either 0%, 1%, 5% or 10% v/v blood. Simultaneous detection of the two target sequences using 10 chemiluminescent probes was substantially as described by Nelson et al. (1996, *Biochem.* 35:8429-8438 at 8432) using an *ortho*-F- AE labeled probe specific for the *C. trachomatis* target polynucleotide and a 2-Me-AE labeled probe specific for the *N. gonorrhoeae* target polynucleotide. The urine samples were prepared and incubated at 60°C for 30 min, and then at 40°C for 30 min for the successive hybridization steps substantially as described in Example 5 herein, except that 15 the blood contaminant was included in some of the samples as described above. The immobilized probes in hybridization complexes were purified using the magnetic field and washing steps, and the purified target sequences were amplified using transcription-associated amplification procedures that included primers specific for the *C. trachomatis* target polynucleotide and the *N. gonorrhoeae* target polynucleotide as described in Examples 4 and 5 above. The detection reagent was added and 20 simultaneous chemiluminescence was detected from the *C. trachomatis* -specific labeled probe the *N. gonorrhoeae* -specific labeled probe. For each type of sample assayed, four replicates were assayed and the RLU results (mean values for each type of sample) are presented in Table 6. In Table 6, the signal (RLU) detected for the *C. trachomatis* -specific labeled probe is indicated by "CT" and the signal detected for the *N. gonorrhoeae* -specific labeled probe is indicated by "NG."

Table 6

	Negative Control	<i>C. trachomatis</i> Target	<i>N. gonorrhoeae</i> Target	<i>C. trachomatis</i> + <i>N. gonorrhoeae</i> Target
5	No Blood	CT: 1 NG: 1.86×10^2	CT: 2.18×10^5 NG: 4.05×10^2	CT: 4.90×10^3 NG: 9.37×10^5
	1% Blood	CT: 52 NG: 4.41×10^2	CT: 2.73×10^5 NG: 1.38×10^3	CT: 4.64×10^3 NG: 9.54×10^5
	5% Blood	CT: 27 NG: 4.42×10^2	CT: 1.91×10^5 NG: 1.66×10^3	CT: 0 NG: 1.06×10^6
	10% Blood	CT: 14 NG: 1.36×10^2	CT: 2.13×10^5 NG: 1.85×10^3	CT: 0 NG: 1.05×10^6

The results presented in Table 6 show that the two-step hybridization assay can be used to detect two targets in a single sample simultaneously. The negative controls gave essentially negligible signals compared to those of the samples that contained the *C. trachomatis* target alone, the *N. gonorrhoeae* target alone, or the combined targets. Detection of either target was not interfered with by up to 10% v/v blood contamination, and both targets were detected simultaneously in a single sample even with blood contamination up to 10% v/v.

15 While several embodiments of the present invention have been described herein, various modifications to the particular probes may be made without departing from the spirit and scope of the present invention which is defined by the claims that follow.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Gen-Probe Incorporated

(ii) TITLE OF INVENTION: Two-Step Hybridization and Capture of a Polynucleotide

(iii) NUMBER OF SEQUENCES: 2

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Gen-Probe Incorporated
(B) STREET: 10210 Genetic Center Drive
(C) CITY: San Diego
(D) STATE: California
(E) COUNTRY: USA
(F) ZIP: 92121-4362

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
(B) COMPUTER: IBM compatible
(C) OPERATING SYSTEM: Microsoft MS-DOS (Version 6.0)
(D) SOFTWARE: FastSeq

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: Unknown
(B) FILING DATE: May 01, 1998
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

Prior applications total,
including application
described below:

(A) APPLICATION NUMBER: US 60/045,430
(B) FILING DATE: May 02, 1997

(A) APPLICATION NUMBER:
(B) FILING DATE:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Christine Gritzmacher
(B) REGISTRATION NUMBER: 40,627
(C) REFERENCE/DOCKET NUMBER: GP088-PCT

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 619 410-8926
(B) TELEFAX: 619 410-8928

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 40
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GAAC TACTTA GTTCCAATGA CTGTTAAAAA AAAAAAAA

40

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

CAGTCATTGG AACTAAGTAG TTC

23

Claims

1. A method of capturing a target polynucleotide present in a sample, comprising the steps of:
 - a) incubating a mixture comprising a target polynucleotide, a capture probe, and an immobilized probe in a first hybridization condition that favors formation of a capture probe:target hybridization complex comprising the capture probe and the target polynucleotide, wherein the first hybridization condition disfavors formation of an immobilized probe:capture probe hybridization complex comprising the immobilized probe and the capture probe; and
 - b) then incubating the mixture in a second hybridization condition that favors formation of the immobilized probe:capture probe hybridization complex, thereby capturing the target polynucleotide in an immobilized probe:capture probe:target hybridization complex comprising the immobilized probe, the capture probe and the target polynucleotide.
2. The method of Claim 1, wherein the first incubating step uses a temperature below a T_m of the capture probe:target hybridization complex and above a T_m of the immobilization probe:capture probe hybridization complex, and wherein the second incubating step uses a temperature below a T_m of the immobilization probe:capture probe hybridization complex.
3. The method of Claim 2, wherein the second incubating step comprises lowering the temperature of the first hybridization condition by at least about 10°C.
4. The method of Claim 2, wherein the second incubating step comprises lowering the temperature of the first hybridization condition by at least about 20°C.
5. The method of Claim 2, wherein the first incubating step uses a temperature of about 60°C and the second incubating step uses a temperature of about 40°C or lower.
6. The method of any one of Claims 1 to 5, further comprising the step of purifying the immobilized probe:capture probe:target hybridization complex.
- 25 7. The method of any one of claims 1 to 6, further comprising the step of detecting the target polynucleotide in the immobilized probe:capture probe:target hybridization complex by hybridizing a labeled probe to the target polynucleotide and detecting the labeled probe.
8. The method of any one of claims 1 to 7, further comprising the step of amplifying the target polynucleotide to produce an amplified nucleic acid.
- 30 9. The method of claim 8, wherein the amplifying step comprises transcription-associated amplification.

10. The method of claim 8 or claim 9, further comprising the step of detecting the amplified nucleic acid.
11. The method of claim 10, wherein the detecting step comprises hybridizing a labeled probe to the amplified nucleic acid which is complementary to the target polynucleotide and detecting the labeled probe.
- 5 12. The method of claim 7 or 11, wherein the detecting step further comprises removing unhybridized labeled probe.
13. The method of any one of claims 1 to 12, wherein both incubating steps include:
the immobilized probe comprising a capture probe-binding region of at least five nucleotide
10 base recognition groups in length, and
the capture probe comprising an immobilized probe-binding region of at least five nucleotide base recognition groups in length,
wherein the capture probe-binding region is complementary to the immobilized probe-binding region.
14. The method of claim 13,
15 wherein the capture probe-binding region comprises:
 - (a) a first backbone containing at least one sugar-phosphodiester linkage, or at least one peptide nucleic acid group, at least one phosphorothioate linkage, or a combination thereof, and
 - (b) at least ten nucleotide base recognition groups joined to the first backbone,
20 wherein each nucleotide recognition group is capable of hydrogen bonding with adenine, guanine, cytosine, thymine, uracil or inosine;
and wherein the immobilized probe-binding region comprises:
 - (a) a second backbone containing at least one sugar-phosphodiester linkage, or at least one peptide nucleic acid group, at least one phosphorothioate linkage, or a combination thereof, and
 - (b) at least ten nucleotide base recognition groups joined to the second backbone,
25 which are capable of hydrogen bonding to the nucleotide base recognition groups joined to the first backbone.
15. The method of claim 13 or claim 14, wherein the capture probe-binding region consists of a homopolymer comprising at least 10 nucleotides, and the immobilized probe-binding region consists of a homopolymer comprising at least 25 nucleotides, of which at least 10
30 nucleotides are complementary to the 10 nucleotides of the capture probe-binding region.

16. The method of any one of claims 13 to 15, wherein the capture probe-binding region comprises about fourteen contiguous A or T bases, and the immobilized probe-binding region comprises a sequence of about 30 bases complementary thereto.
17. The method of any one of claims 1 to 16, wherein the incubating steps use a mixture comprising the immobilized probe and the capture probe, wherein each probe comprises deoxynucleotide, ribonucleotide, 2'-methoxy substituted nucleotide, 2'-halo substituted nucleotide components, or combinations thereof.
18. A method for determining the presence of a target polynucleotide in a sample, comprising the steps of:
 - 10 a. providing a capture probe capable of hybridizing to a target polynucleotide present in a sample;
 - b. mixing the capture probe with a sample suspected of containing the target polynucleotide at a first incubation temperature that favors hybridization of the capture probe and the target polynucleotide, thereby producing a capture probe:target polynucleotide complex;
 - c. providing an immobilized probe capable of hybridizing to the capture probe;
 - d. incubating the capture probe:target polynucleotide complex and the immobilization probe at a second incubation temperature that favors hybridization of the immobilized probe and the capture probe, thereby producing a captured target polynucleotide comprising an immobilized probe:capture probe:target polynucleotide complex;
 - e. purifying the captured target polynucleotide, thereby producing a purified target polynucleotide;
 - f. amplifying the purified target polynucleotide, thereby producing an amplified nucleic acid; and
 - 25 g. detecting the amplified nucleic acid to determine the presence of the target polynucleotide in the sample.
19. The method of Claim 18, wherein the detecting step comprises hybridizing a labeled probe to the amplified nucleic acid which is complementary to the target polynucleotide or a portion thereof and detecting the labeled probe.

1/4




FIG. 1A










FIG. 1B

2/4

FIG. 2A**FIG. 2B****FIG. 2C****FIG. 2D****FIG. 2E****FIG. 2F**

3/4




FIG. 3A




FIG. 3B




FIG. 3C

4/4




FIG. 4

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/08853

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12Q1/68

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 328 829 A (AMOCO CORP) 23 August 1989 see the whole document ---	1-19
X	EP 0 265 244 A (AMOCO CORP) 27 April 1988 see the whole document ---	1-19
A	EP 0 526 912 A (ENZO BIOCHEM INC) 10 February 1993 cited in the application -----	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

4 September 1998

Date of mailing of the international search report

11/09/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Molina Galan, E

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte onal Application No
PCT/US 98/08853

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0328829	A 23-08-1989	AT 127854 T AU 2735988 A DE 3854470 D DE 3854470 T JP 1211500 A US 5750338 A US 5714380 A		15-09-1995 13-07-1989 19-10-1995 28-03-1996 24-08-1989 12-05-1998 03-02-1998
EP 0265244	A 27-04-1988	AU 621812 B AU 8009787 A CA 1309329 A CN 1016645 B DE 3781860 A JP 63188399 A US 5780224 A US 5750338 A US 5714380 A ZA 8707772 A		26-03-1992 28-04-1988 27-10-1992 13-05-1992 29-10-1992 03-08-1988 14-07-1998 12-05-1998 03-02-1998 20-04-1988
EP 0526912	A 10-02-1993	AU 4148685 A AU 4598489 A CA 1260372 A DE 3587427 A DE 3587427 T DK 188385 A EP 0159719 A JP 2735822 B JP 8336400 A JP 2560003 B JP 60237361 A US 4894325 A US 5288609 A		30-01-1986 29-03-1990 26-09-1989 05-08-1993 20-01-1994 28-10-1985 30-10-1985 02-04-1998 24-12-1996 04-12-1996 26-11-1985 16-01-1990 22-02-1994